Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Professional Care Providers
- Remove Family & Advocates
- Remove Program Planners, Administrators, & Project Managers
- Remove Substance Abuse
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Children of Parents with Substance Use or Abuse Problems
- Remove Practitioner/Professional
- Remove Opioids or Opiates
- Remove Heroin
- Remove Methadone
- Remove Opium
- Remove Medication-Assisted Treatment
- Remove Naloxone
Main page content
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants
Published: January 2018This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.